---
title: "WuXi Biologics Board to Approve Annual Results"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275524667.md"
datetime: "2026-02-10T23:32:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275524667.md)
  - [en](https://longbridge.com/en/news/275524667.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275524667.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275524667.md) | [繁體中文](https://longbridge.com/zh-HK/news/275524667.md)


# WuXi Biologics Board to Approve Annual Results

Wuxi Biologics (Cayman) Inc. has announced that its Board of Directors will hold a meeting on Tuesday, March 24, 2026. The purpose of the meeting includes considering and approving the annual results of the Group for the year ended December 31, 2025, as well as its publication. For more information, refer to the official announcement from the company. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260211-12021320), on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相关股票

- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-CN/quote/588250.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-CN/quote/159859.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-CN/quote/512010.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-CN/quote/516820.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md)
- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-CN/quote/560600.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md)
- [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-CN/quote/159102.CN.md)
- [WUXI BIO (02269.HK)](https://longbridge.com/zh-CN/quote/02269.HK.md)
- [WuXi Biologics (WXXWY.US)](https://longbridge.com/zh-CN/quote/WXXWY.US.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-CN/quote/588860.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md)

## 相关资讯与研究

- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/zh-CN/news/281458440.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-CN/news/281231901.md)
- [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/zh-CN/news/281662341.md)
- [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/zh-CN/news/280923090.md)
- [Endo GUC Trust Provides Its 2025 Report](https://longbridge.com/zh-CN/news/281234549.md)